{
  "id": 3952978,
  "title": "Roche bets $1B+ on DualityBio's ADC tech to tackle TOPO1 resistance",
  "url": "https://urgent.news/2026/08/28/roche-bets-1b-on-dualitybios-adc-tech-to-tackle-topo1-resistance",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-28T11:30:02.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/roche-bets-1b-on-dualitybios-adc-tech-to-tackle-topo1-resistance/"
  },
  "original_language": "en",
  "account": null,
  "summary": "DualityBio said Friday it will receive $45 million upfront from Roche’s Genentech to develop drugs that could be part of a new wave of antibody-drug conjugates. The deal is centered on ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}